Work

KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps4209

Authors: Ken Kato, Toshihiko Doi, Antoine Adenis, Manish A. Shah, Peter C. Enzinger, Lin Shen, Tatiane Cristine Ishida, Leah Suttner, Kanu Sharan, Pooja Bhagia, Jong-Mu Sun

Institutions: National Cancer Center Hospital, National Cancer Center Hospital East, Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier, NewYork–Presbyterian Hospital, Dana-Farber Cancer Institute, Peking University Cancer Hospital, Daiichi Sankyo (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Samsung Medical Center, Sungkyunkwan University

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410815509

FWCI:

Cites:

Cited by:

Related to: 10